In stock COA-30%
NOVALYTE
LABS
LABS
NOVALYTELABS
VK27355mg · RESEARCH USE ONLY
VK27355mg · RESEARCH USE ONLY
In stock COA DOCUMENT SLOT-30%
Metabolic ResearchVK2735
Next-generation dual GLP-1/GIP receptor agonist by Viking Therapeutics — studied for superior appetite suppression and metabolic regulation.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch
Product information
CompoundVK2735
Presentation5mg injection pen
CategoryMetabolic Research
AvailabilityIn stock
Batch COACertificate supplied with order
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
VK2735 is a novel dual GLP-1/GIP receptor agonist developed by Viking Therapeutics, currently in advanced clinical trials for obesity and metabolic disorders. Phase 2 data demonstrated average weight loss of 14.7% with the injectable form and 12.2% with the oral tablet over a short trial period — positioning it among the most potent metabolic research compounds in development. VK2735 targets both incretin receptor pathways simultaneously, building on the dual-agonist approach pioneered by tirzepatide with potential pharmacokinetic improvements.
Mechanism of Action
VK2735 activates two key incretin receptors: GLP-1R and GIPR. GLP-1 receptor agonism suppresses appetite via hypothalamic POMC/CART neuron activation, delays gastric emptying, and enhances glucose-dependent insulin secretion. Concurrent GIP receptor activation modulates adipose tissue function and may enhance central satiety signalling through complementary hypothalamic pathways. The dual mechanism produces synergistic metabolic effects — greater appetite suppression, improved glucose disposal, and enhanced energy expenditure — beyond what either receptor pathway achieves alone.
Research Applications
- Dual incretin receptor pharmacology and signalling research
- Next-generation obesity compound comparative studies
- Appetite regulation and hypothalamic pathway investigation
- Glucose homeostasis and insulin sensitivity models
- GLP-1/GIP receptor crosstalk and synergy research